Zsuzsanna Helyes

Professor in pharmacology

Role in PharmNovo: Consultant and scientific advisor.

University/company: University of Pecs / PharmInVivo.

Resumé: Dr Helyes work in the fields of pain and inflammation and has great expertise in a variety of experimental models with special emphasis on in vivo studies. She also started PharmInVivo and today lead the company which is a spin-out company based in the Department of Pharmacology and Pharmacotherapy at the Medical Faculty & Szentagothai Research Center of the University of Pécs. The team focuses on animal models of chronic diseases and has a complete repertoire of nociceptive tests in both rats and mice.

Member of:

Pain

Latest news

View all

October 10, 2024

PharmNovo at the LSX Nordic Congress

PharmNovo attended the LSX Nordic Congress in Copenhagen 8-9 October and Per von Mentzer, CEO presented PN6047, a unique first-in-class phase II ready asset with break-through potential in treatment of neuropathic pain. Being one of 68 companies that have recently been awarded by EIC for up to 17.5 MEUR (2.5 MEUR grant and up to 15 MEUR equity) from a total of 969 applicants is a strong validation of the potential of the phase II ready asset PN6047 and of PharmNovo. Take the opportunity to listen to the presentation here:

July 17, 2024

17.5 MEUR blended funding from EIC

PharmNovo is very pleased to announce that we have been awarded a 2.5 MEUR grant and an opportunity for up to 15 MEUR equity investment from the European Innovation Council (EIC) for innovative pain treatment. The equity part being contingent on investments of equal amounts from co-investors.

PharmNovo presenting at the Global Forum

June 5, 2024

PharmNovo presenting at the Global Forum

On May 29–30, BioStock hosted the Global Forum. The event is the first of its kind, aimed at bringing together growth stage Nordic life science companies looking to expand into new markets and experts armed with a profound knowledge of how business is done across the globe.

March 21, 2024

Positive final Phase I results

The final results from the Phase I clinical for our neuropathic pain drug candidate PN6047, demonstrates safety and tolerability and a lack of the adverse effects commonly associated with conventional opioids. The findings from the Phase I trial show that PN6047 is safe and well-tolerated at the doses tested, with no serious adverse events reported.